{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:46:10Z","timestamp":1769071570233,"version":"3.49.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cisplatin administration is the primary chemotherapy approach for many epithelial cancers. However, resistance to this drug poses a significant challenge to effective treatment. Despite the identification of numerous factors associated with resistance, reliable biomarkers predicting drug response remain elusive. Previously, low expression of the NPRL2 tumor suppressor was linked to cisplatin resistance. NPRL2, along with NPRL3 and DEPDC5, forms the GATOR1 complex, an upstream regulator of the mTOR\u04211, the function of which is perturbed in many cancers, particularly those resistant to cisplatin. Here, we compare non-cancerous bronchial epithelium BEAS-2B cells with GATOR1 deletions, serving as a model of intrinsic cisplatin resistance, with non-small cell lung cancer lines A549, H460, and H1975 with acquired resistance to the drug. We found that deletion of any GATOR1 member, not solely NPRL2, promotes cisplatin resistance, whereas their overexpression renders cells sensitive to the drug. In cells with GATOR1 deletions, expression of the ATP7A transporter required for cisplatin efflux is increased, while expression of cisplatin influx transporters CTR2 and LRRC8A is downregulated, especially after treatment with the drug. This hinders drug accumulation in cells, resulting in the formation of fewer cisplatin-DNA adducts. Simultaneously, these cells exhibit enhanced DNA damage response and mTORC1 activity. Overexpression of GATOR1 components and\/or concomitant treatment with an mTORC1 inhibitor restores sensitivity to cisplatin. Transcriptomic analysis of GATOR1-deleted BEAS-2B cells, treated or not with the drug, identifies new signatures important for understanding GATOR1 function and its role in cisplatin resistance. Thus, GATOR1 not only participates in the cellular response to amino acid availability but also plays a role in resistance to DNA-damaging anticancer drugs. This novel function of GATOR1 should be taken into account when developing new strategies to combat chemoresistance.<\/jats:p>","DOI":"10.1038\/s41419-025-08392-4","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:35:33Z","timestamp":1767116133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GATOR1 complex controls cisplatin sensitivity"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-5197","authenticated-orcid":false,"given":"Zhenrui","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4773-317X","authenticated-orcid":false,"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6032-622X","authenticated-orcid":false,"given":"Svetlana","family":"Dokudovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"8392_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10608","volume":"8","author":"R Ranasinghe","year":"2022","unstructured":"Ranasinghe R, Mathai ML, Zulli A. Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon. 2022;8.e10608.","journal-title":"Heliyon"},{"key":"8392_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21:37\u201350.","journal-title":"Nat Rev Cancer"},{"key":"8392_CR3","unstructured":"Cancer Today. http:\/\/gco.iarc.fr\/today\/home."},{"key":"8392_CR4","doi-asserted-by":"publisher","first-page":"8885","DOI":"10.3390\/ijms22168885","volume":"22","author":"J Kryczka","year":"2021","unstructured":"Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, Brzezia\u0144ska-Lasota E. Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. IJMS. 2021;22:8885.","journal-title":"IJMS"},{"key":"8392_CR5","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.15252\/embj.201592409","volume":"34","author":"R Planells-Cases","year":"2015","unstructured":"Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, et al. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J. 2015;34:2993\u20133008.","journal-title":"EMBO J"},{"key":"8392_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1124\/mol.109.063172","volume":"77","author":"SB Howell","year":"2010","unstructured":"Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010;77:887\u201394.","journal-title":"Mol Pharmacol"},{"key":"8392_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"key":"8392_CR8","doi-asserted-by":"publisher","first-page":"9100","DOI":"10.1074\/jbc.M210284200","volume":"278","author":"A Mandic","year":"2003","unstructured":"Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 2003;278:9100\u20136.","journal-title":"J Biol Chem"},{"key":"8392_CR9","doi-asserted-by":"publisher","first-page":"15410","DOI":"10.3390\/ijms232315410","volume":"23","author":"BN Forgie","year":"2022","unstructured":"Forgie BN, Prakash R, Telleria CM. Revisiting the anti-cancer toxicity of clinically approved platinating derivatives. IJMS. 2022;23:15410.","journal-title":"IJMS"},{"key":"8392_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.428","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Disease. 2014;5:e1257.","journal-title":"Cell Death Disease"},{"key":"8392_CR11","doi-asserted-by":"publisher","first-page":"10651","DOI":"10.3390\/ijms241310651","volume":"24","author":"Z Pan","year":"2023","unstructured":"Pan Z, Zhang H, Dokudovskaya S. The role of mTORC1 pathway and autophagy in resistance to platinum-based chemotherapeutics. Int J Mol Sci. 2023;24:10651.","journal-title":"Int J Mol Sci"},{"key":"8392_CR12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.bbamcr.2018.06.011","volume":"1865","author":"Y Ma","year":"2018","unstructured":"Ma Y, Vassetzky Y, Dokudovskaya S. mTORC1 pathway in DNA damage response. Biochim Biophys Acta (BBA)\u2014Mol Cell Res. 2018;1865:1293\u2013311.","journal-title":"Biochim Biophys Acta (BBA)\u2014Mol Cell Res"},{"key":"8392_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21:183\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8392_CR14","first-page":"75","volume":"25","author":"JH Ren","year":"2010","unstructured":"Ren JH, He WS, Nong L, Zhu QY, Hu K, Zhang RG, et al. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm. 2010;25:75\u201380.","journal-title":"Cancer Biother Radiopharm"},{"key":"8392_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18504-7","volume":"11","author":"N Gremke","year":"2020","unstructured":"Gremke N, Polo P, Dort A, Schneikert J, Elmsh\u00e4user S, Brehm C, et al. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun. 2020;11:4684.","journal-title":"Nat Commun"},{"key":"8392_CR16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1242\/jcs.168922","volume":"128","author":"S Dokudovskaya","year":"2015","unstructured":"Dokudovskaya S, Rout MP. SEA you later alli-GATOR\u2014a dynamic regulator of the TORC1 stress response pathway. J Cell Sci. 2015;128:2219\u201328.","journal-title":"J Cell Sci"},{"key":"8392_CR17","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/cells10102689","volume":"10","author":"YA Loissell-Baltazar","year":"2021","unstructured":"Loissell-Baltazar YA, Dokudovskaya S. SEA and GATOR 10 years later. Cells. 2021;10:2689.","journal-title":"Cells"},{"key":"8392_CR18","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013;340:1100\u20136.","journal-title":"Science"},{"key":"8392_CR19","doi-asserted-by":"crossref","unstructured":"Panchaud N, P\u00e9li-Gulli MP, De Virgilio C. Amino acid deprivation inhibits TORC1 through a GTPase-activating protein complex for the Rag family GTPase Gtr1. Sci Signal. 2013;6:ra42.","DOI":"10.1126\/scisignal.2004112"},{"key":"8392_CR20","doi-asserted-by":"publisher","first-page":"9682","DOI":"10.1158\/0008-5472.CAN-06-1483","volume":"66","author":"K Ueda","year":"2006","unstructured":"Ueda K, Kawashima H, Ohtani S, Deng WGG, Ravoori M, Bankson J, et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 2006;66:9682\u201390.","journal-title":"Cancer Res"},{"key":"8392_CR21","doi-asserted-by":"publisher","first-page":"15311","DOI":"10.1038\/s41598-017-15497-0","volume":"7","author":"Y Ma","year":"2017","unstructured":"Ma Y, Silveri L, LaCava J, Dokudovskaya S. Tumor suppressor NPRL2 induces ROS production and DNA damage response. Sci Rep. 2017;7:15311.","journal-title":"Sci Rep"},{"key":"8392_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbrc.2009.08.027","volume":"388","author":"A Lunardi","year":"2009","unstructured":"Lunardi A, Chiacchiera F, D\u2019Este E, Carotti M, Dal Ferro M, Di Minin G, et al. The evolutionary conserved gene C16orf35 encodes a nucleo-cytoplasmic protein that interacts with p73. Biochem Biophys Res Commun. 2009;388:428\u201333.","journal-title":"Biochem Biophys Res Commun"},{"key":"8392_CR23","doi-asserted-by":"publisher","first-page":"e0181081","DOI":"10.1371\/journal.pone.0181081","volume":"12","author":"N Sarin","year":"2017","unstructured":"Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J, Rothweiler F, et al. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2\/M cell cycle arrest. PLoS ONE. 2017;12:e0181081.","journal-title":"PLoS ONE"},{"key":"8392_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/1462-2920.14708","volume":"22","author":"M Amor","year":"2020","unstructured":"Amor M, Tharaud M, G\u00e9labert A, Komeili A. Single-cell determination of iron content in magnetotactic bacteria: implications for the iron biogeochemical cycle. Environ Microbiol. 2020;22:823\u201331.","journal-title":"Environ Microbiol"},{"key":"8392_CR25","doi-asserted-by":"publisher","first-page":"e11994","DOI":"10.1371\/journal.pone.0011994","volume":"5","author":"G Jayachandran","year":"2010","unstructured":"Jayachandran G, Ueda K, Wang B, Roth JA, Ji L. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS ONE. 2010;5:e11994.","journal-title":"PLoS ONE"},{"key":"8392_CR26","first-page":"1904","volume":"48","author":"RR Reddel","year":"1988","unstructured":"Reddel RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, Su RT, et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res. 1988;48:1904\u20139.","journal-title":"Cancer Res"},{"key":"8392_CR27","doi-asserted-by":"publisher","first-page":"e53367","DOI":"10.7554\/eLife.53367","volume":"9","author":"JF Hastings","year":"2020","unstructured":"Hastings JF, Gonzalez Rajal A, Latham SL, Han JZ, McCloy RA, O\u2019Donnell YE, et al. Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. eLife. 2020;9:e53367.","journal-title":"eLife"},{"key":"8392_CR28","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1158\/0008-5472.CAN-12-3000","volume":"73","author":"J Michels","year":"2013","unstructured":"Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013;73:2271\u201380.","journal-title":"Cancer Res"},{"key":"8392_CR29","doi-asserted-by":"crossref","unstructured":"Obrist F, Michels J, Durand S, Chery A, Pol J, Levesque S, et al. Metabolic vulnerability of cisplatin-resistant cancers. EMBO J. 2018;37:e98597.","DOI":"10.15252\/embj.201798597"},{"key":"8392_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.semcancer.2021.05.023","volume":"76","author":"F Arnesano","year":"2021","unstructured":"Arnesano F, Natile G. Interference between copper transport systems and platinum drugs. Semin Cancer Biol. 2021;76:173\u201388.","journal-title":"Semin Cancer Biol"},{"key":"8392_CR31","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1158\/2767-9764.CRC-22-0208","volume":"2","author":"CA Widmer","year":"2022","unstructured":"Widmer CA, Klebic I, Domanitskaya N, Decollogny M, Howald D, Siffert M, et al. Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy. Cancer Res Commun. 2022;2:1266\u201381.","journal-title":"Cancer Res Commun"},{"key":"8392_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/cells8091080","volume":"8","author":"R Petruzzelli","year":"2019","unstructured":"Petruzzelli R, Polishchuk RS. Activity and trafficking of copper-transporting ATPases in tumor development and defense against platinum-based drugs. Cells. 2019;8:1080.","journal-title":"Cells"},{"key":"8392_CR33","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1093\/bioinformatics\/btq466","volume":"26","author":"A Lachmann","year":"2010","unstructured":"Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma\u2019ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics. 2010;26:2438\u201344.","journal-title":"Bioinformatics"},{"key":"8392_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/cells11020219","volume":"11","author":"R Petruzzelli","year":"2022","unstructured":"Petruzzelli R, Mariniello M, De Cegli R, Catalano F, Guida F, Di Schiavi E, et al. TFEB regulates ATP7B expression to promote platinum chemoresistance in human ovarian cancer cells. Cells. 2022;11:219.","journal-title":"Cells"},{"key":"8392_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05862-6","volume":"9","author":"G Napolitano","year":"2018","unstructured":"Napolitano G, Esposito A, Choi H, Matarese M, Benedetti V, Di Malta C, et al. mTOR-dependent phosphorylation controls TFEB nuclear export. Nat Commun. 2018;9:3312.","journal-title":"Nat Commun"},{"key":"8392_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41420-021-00519-8","volume":"7","author":"W Liu","year":"2021","unstructured":"Liu W, Wang Y, Xie Y, Dai T, Fan M, Li C, et al. Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer. Cell Death Discov. 2021;7:136.","journal-title":"Cell Death Discov"},{"key":"8392_CR37","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.18632\/aging.101669","volume":"10","author":"P Lopriore","year":"2018","unstructured":"Lopriore P, Capitanio N, Panatta E, Di Daniele N, Gambacurta A, Melino G, et al. TAp73 regulates ATP7A: possible implications for ageing-related diseases. Aging. 2018;10:3745\u201360.","journal-title":"Aging"},{"key":"8392_CR38","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2022.04.013","volume":"185","author":"S Battaglioni","year":"2022","unstructured":"Battaglioni S, Benjamin D, W\u00e4lchli M, Maier T, Hall MN. mTOR substrate phosphorylation in growth control. Cell. 2022;185:1814\u201336.","journal-title":"Cell"},{"key":"8392_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20184","volume":"9","author":"HF Wei","year":"2023","unstructured":"Wei HF, Zhang RF, Zhao YC, Tong XS. SERPINB7 as a prognostic biomarker in cervical cancer: association with immune infiltration and facilitation of the malignant phenotype. Heliyon. 2023;9:e20184.","journal-title":"Heliyon"},{"key":"8392_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tranon.2018.08.019","volume":"12","author":"D Bianconi","year":"2019","unstructured":"Bianconi D, Herac M, Spies D, Kieler M, Brettner R, Unseld M, et al. SERPINB7 expression predicts poor pancreatic cancer survival upon gemcitabine treatment. Transl Oncol. 2019;12:15\u201323.","journal-title":"Transl Oncol"},{"key":"8392_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.freeradbiomed.2023.10.391","volume":"209","author":"J Ou","year":"2023","unstructured":"Ou J, Liao Q, Du Y, Xi W, Meng Q, Li K, et al. SERPINE1 and SERPINB7 as potential biomarkers for intravenous vitamin C treatment in non-small-cell lung cancer. Free Radic Biol Med. 2023;209:96\u2013107.","journal-title":"Free Radic Biol Med"},{"key":"8392_CR42","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41417-020-00258-5","volume":"28","author":"T Sang","year":"2021","unstructured":"Sang T, Yang J, Liu J, Han Y, Li Y, Zhou X, et al. AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma. Cancer Gene Ther. 2021;28:1125\u201335.","journal-title":"Cancer Gene Ther"},{"key":"8392_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3892\/etm.2024.12546","volume":"27","author":"H Wang","year":"2024","unstructured":"Wang H, Ye M, Jin X. Role of angiomotin family members in human diseases (Review). Exp Ther Med. 2024;27:258.","journal-title":"Exp Ther Med"},{"key":"8392_CR44","doi-asserted-by":"publisher","first-page":"11834","DOI":"10.3390\/ijms222111834","volume":"22","author":"Y Ma","year":"2021","unstructured":"Ma Y, Nenkov M, Schr\u00f6der DC, Abubrig M, Gassler N, Chen Y. Fibulin 2 Is hypermethylated and suppresses tumor cell proliferation through inhibition of cell adhesion and extracellular matrix genes in non-small cell lung cancer. IJMS. 2021;22:11834.","journal-title":"IJMS"},{"key":"8392_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53272-0","volume":"14","author":"Z Song","year":"2024","unstructured":"Song Z, Gui S, Xiao S, Rao X, Cong N, Deng H, et al. A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer. Sci Rep. 2024;14:3198.","journal-title":"Sci Rep"},{"key":"8392_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1127753","volume":"13","author":"L Chen","year":"2023","unstructured":"Chen L, He Y, Han Z, Gong W, Tian X, Guo L, et al. The impact of decreased expression of SVEP1 on abnormal neovascularization and poor prognosis in patients with intrahepatic cholangiocarcinoma. Front Genet. 2023;13:1127753.","journal-title":"Front Genet"},{"key":"8392_CR47","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2147\/CMAR.S246625","volume":"12","author":"R Jia","year":"2020","unstructured":"Jia R, Wang C. MiR-29b-3p reverses cisplatin resistance by targeting COL1A1 in non-small-cell lung cancer A549\/DDP cells. CMAR. 2020;12:2559\u201366.","journal-title":"CMAR"},{"key":"8392_CR48","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41418-024-01370-x","volume":"31","author":"I Livneh","year":"2024","unstructured":"Livneh I, Fabre B, Goldhirsh G, Lulu C, Zinger A, Shammai Vainer Y, et al. Inhibition of nucleo-cytoplasmic proteasome translocation by the aromatic amino acids or silencing Sestrin3\u2014their sensing mediator\u2014is tumor suppressive. Cell Death Differ. 2024;31:1242\u201354.","journal-title":"Cell Death Differ"},{"key":"8392_CR49","first-page":"512","volume":"50","author":"W Duan","year":"2020","unstructured":"Duan W, Liu X. PSAT1 upregulation contributes to cell growth and cisplatin resistance in cervical cancer cells via regulating PI3K\/AKT signaling pathway. Ann Clin Lab Sci. 2020;50:512\u20138.","journal-title":"Ann Clin Lab Sci"},{"key":"8392_CR50","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3389\/fonc.2019.01480","volume":"9","author":"M Chiu","year":"2020","unstructured":"Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O. Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front Oncol. 2020;9:1480.","journal-title":"Front Oncol"},{"key":"8392_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-224","volume":"6","author":"P Zhang","year":"2006","unstructured":"Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer. 2006;6:224.","journal-title":"BMC Cancer"},{"key":"8392_CR52","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.3892\/or.2020.7803","volume":"44","author":"R Li","year":"2020","unstructured":"Li R, Wang W, Yang Y, Gu C. Exploring the role of glucose\u20116\u2011phosphate dehydrogenase in cancer (Review). Oncol Rep. 2020;44:2325\u201336.","journal-title":"Oncol Rep"},{"key":"8392_CR53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000489801","volume":"47","author":"M Deng","year":"2018","unstructured":"Deng M, Yu R, Wang S, Zhang Y, Li Z, Song H, et al. Limb-Bud and heart attenuates growth and invasion of human lung adenocarcinoma cells and predicts survival outcome. Cell Physiol Biochem. 2018;47:223\u201334.","journal-title":"Cell Physiol Biochem"},{"key":"8392_CR54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10103-018-2616-4","volume":"34","author":"H Yang","year":"2019","unstructured":"Yang H, Wan Z, Huang C, Yin H, Song D. AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras\u2013Raf\u2013MEK\u2013ERK signal pathway. Lasers Med Sci. 2019;34:473\u20138.","journal-title":"Lasers Med Sci"},{"key":"8392_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41698-024-00566-1","volume":"8","author":"Y Kim","year":"2024","unstructured":"Kim Y, You JH, Ryu Y, Park G, Lee U, Moon HE, et al. ELAVL2 loss promotes aggressive mesenchymal transition in glioblastoma. npj Precis Onc. 2024;8:79.","journal-title":"npj Precis Onc"},{"key":"8392_CR56","doi-asserted-by":"publisher","first-page":"8832","DOI":"10.1093\/nar\/gky589","volume":"46","author":"YY Lee","year":"2018","unstructured":"Lee YY, Mok MT, Kang W, Yang W, Tang W, Wu F, et al. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. Nucleic Acids Res. 2018;46:8832\u201347.","journal-title":"Nucleic Acids Res"},{"key":"8392_CR57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/ijms19030767","volume":"19","author":"N Sarin","year":"2018","unstructured":"Sarin N, Engel F, Rothweiler F, Cinatl J, Michaelis M, Fr\u00f6tschl R, et al. Key players of cisplatin resistance: towards a systems pharmacology approach. IJMS. 2018;19:767.","journal-title":"IJMS"},{"key":"8392_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1970","volume":"7","author":"SH Sheikhshabani","year":"2024","unstructured":"Sheikhshabani SH, Modarres P, Ghafouri-Fard S, Amini-Farsani Z, Khodaee L, Shaygan N, et al. Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer. Cancer Reports. 2024;7:e1970.","journal-title":"Cancer Reports"},{"key":"8392_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.146668","volume":"834","author":"A Khalaji","year":"2022","unstructured":"Khalaji A, Haddad S, Yazdani Y, Moslemi M, Alizadeh L, Baradaran B. A bioinformatics-based study on the cisplatin-resistant lung cancer cells; what are the orchestrators of this phenom? Gene. 2022;834:146668.","journal-title":"Gene"},{"key":"8392_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fphar.2018.00043","volume":"9","author":"W Hong","year":"2018","unstructured":"Hong W, Cai P, Xu C, Cao D, Yu W, Zhao Z, et al. Inhibition of glucose-6-phosphate dehydrogenase reverses cisplatin resistance in lung cancer cells via the redox system. Front Pharmacol. 2018;9:43.","journal-title":"Front Pharmacol"},{"key":"8392_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0270-x","volume":"16","author":"L Zhang","year":"2018","unstructured":"Zhang L, Li X, Chao Y, He R, Liu J, Yuan Y, et al. KLF4, a miR-32-5p targeted gene, promotes cisplatin-induced apoptosis by upregulating BIK expression in prostate cancer. Cell Commun Signal. 2018;16:53.","journal-title":"Cell Commun Signal"},{"key":"8392_CR62","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12672-024-01576-y","volume":"15","author":"W Zhou","year":"2024","unstructured":"Zhou W, Huang H, Teng Y, Hua R, Hu Y, Li X. KLF4 promotes cisplatin resistance by activating mTORC1 signaling in ovarian cancer. Discov Onc. 2024;15:682.","journal-title":"Discov Onc"},{"key":"8392_CR63","first-page":"6116","volume":"60","author":"MI Lerman","year":"2000","unstructured":"Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res. 2000;60:6116\u201333.","journal-title":"Cancer Res"},{"key":"8392_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03860-z","volume":"12","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Guo J, Wang X, Cheng Y, Guan J, Barman P, et al. FKBP39 controls nutrient dependent Nprl3 expression and TORC1 activity in Drosophila. Cell Death Dis. 2021;12:571.","journal-title":"Cell Death Dis"},{"key":"8392_CR65","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/hep4.2019","volume":"6","author":"YC Wang","year":"2022","unstructured":"Wang YC, Tsai MC, Chen YS, Hsieh PM, Hung CM, Lin HY, et al. NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. Hepatol Commun. 2022;6:3563\u201377.","journal-title":"Hepatol Commun"},{"key":"8392_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.949737","volume":"13","author":"W Jiang","year":"2022","unstructured":"Jiang W, Ou Z, Zhu Q, Zai H. RagC GTPase regulates mTOR to promote chemoresistance in senescence-like HepG2 cells. Front Physiol. 2022;13:949737.","journal-title":"Front Physiol"},{"key":"8392_CR67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nature05528","volume":"445","author":"YC Hsu","year":"2007","unstructured":"Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature. 2007;445:785\u20138.","journal-title":"Nature"},{"key":"8392_CR68","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/0008-5472.CAN-14-2315","volume":"75","author":"Y Peng","year":"2015","unstructured":"Peng Y, Dai H, Wang E, Lin CCJ, Mo W, Peng G, et al. TUSC4 functions as a tumor suppressor by regulating BRCA1 stability. Cancer Res. 2015;75:378\u201386.","journal-title":"Cancer Res"},{"key":"8392_CR69","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/jca.93789","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang M, Zhang H, Lu Z, Su W, Tan Y, Wang J, et al. PSAT1 mediated EMT of colorectal cancer cells by regulating Pl3K\/AKT signaling pathway. J Cancer. 2024;15:3183\u201398.","journal-title":"J Cancer"},{"key":"8392_CR70","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.2147\/OTT.S250066","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Li J, Dong X, Meng D, Zhi X, Yuan L, et al. PSAT1 regulated oxidation-reduction balance affects the growth and prognosis of epithelial ovarian cancer. OTT. 2020;13:5443\u201353.","journal-title":"OTT"},{"key":"8392_CR71","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1080\/00365521.2016.1190399","volume":"51","author":"Q Yu","year":"2016","unstructured":"Yu Q, Wang X, Wang L, Zheng J, Wang J, Wang B. Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells. Scand J Gastroenterol. 2016;51:1220\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"8392_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3892\/ol.2012.1014","volume":"5","author":"T Minegaki","year":"2013","unstructured":"Minegaki T, Takara K, Hamaguchi R, Tsujimoto M, Nishiguchi K. Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett. 2013;5:427\u201334.","journal-title":"Oncol Lett"},{"key":"8392_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2023.105055","volume":"292","author":"X Song","year":"2024","unstructured":"Song X, Wang X, Chen X, Yu Z, Zhou Y. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9\/GCH1 axis. J Proteom. 2024;292:105055.","journal-title":"J Proteom"},{"key":"8392_CR74","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.matbio.2013.05.003","volume":"32","author":"MB Duncan","year":"2013","unstructured":"Duncan MB. Extracellular matrix transcriptome dynamics in hepatocellular carcinoma. Matrix Biol. 2013;32:393\u20138.","journal-title":"Matrix Biol"},{"key":"8392_CR75","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/onc.2009.454","volume":"29","author":"I Ibanez De Caceres","year":"2010","unstructured":"Ibanez De Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Mangu\u00e1n-Garc\u00eda C, et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene. 2010;29:1681\u201390.","journal-title":"Oncogene"},{"key":"8392_CR76","doi-asserted-by":"publisher","first-page":"1690896","DOI":"10.1155\/2016\/1690896","volume":"2016","author":"J Yang","year":"2016","unstructured":"Yang J, Zhang K, Wu J, Shi J, Xue J, Li J, et al. Wnt5a increases properties of lung cancer stem cells and resistance to cisplatin through activation of Wnt5a\/PKC signaling pathway. Stem Cells Int. 2016;2016:1690896.","journal-title":"Stem Cells Int"},{"key":"8392_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07858-8","volume":"10","author":"HV Woodcock","year":"2019","unstructured":"Woodcock HV, Eley JD, Guillotin D, Plat\u00e9 M, Nanthakumar CB, Martufi M, et al. The mTORC1\/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nat Commun. 2019;10:6.","journal-title":"Nat Commun"},{"key":"8392_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154013","volume":"236","author":"X Li","year":"2022","unstructured":"Li X, Sun X, Kan C, Chen B, Qu N, Hou N, et al. COL1A1: A novel oncogenic gene and therapeutic target in malignancies. Pathol\u2014Res Pract. 2022;236:154013.","journal-title":"Pathol\u2014Res Pract"},{"key":"8392_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-108","volume":"14","author":"M Hayashi","year":"2014","unstructured":"Hayashi M, Nomoto S, Hishida M, Inokawa Y, Kanda M, Okamura Y, et al. Identification of the collagen type 1 \u03b1 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer. 2014;14:108.","journal-title":"BMC Cancer"},{"key":"8392_CR80","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.4161\/cc.21789","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Guti\u00e9rrez D, Vacchelli E, et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle. 2012;11:3472\u201380.","journal-title":"Cell Cycle"},{"key":"8392_CR81","doi-asserted-by":"publisher","first-page":"e65309","DOI":"10.1371\/journal.pone.0065309","volume":"8","author":"Y Yang","year":"2013","unstructured":"Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS ONE. 2013;8:e65309.","journal-title":"PLoS ONE"},{"key":"8392_CR82","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1074\/mcp.M500140-MCP200","volume":"5","author":"JJ Stewart","year":"2006","unstructured":"Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, et al. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteom. 2006;5:433\u201343.","journal-title":"Mol Cell Proteom"},{"key":"8392_CR83","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1124\/mol.64.2.259","volume":"64","author":"PW Schenk","year":"2003","unstructured":"Schenk PW, Brok E, Boersma AWM, Brandsma JA, Den Dulk H, Burger H, et al. Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol. 2003;64:259\u201368.","journal-title":"Mol Pharmacol"},{"key":"8392_CR84","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.2147\/OTT.S219562","volume":"12","author":"A Liu","year":"2019","unstructured":"Liu A, Qiao J, He L, Liu Z, Chen J, Pei F, et al. Nitrogen permease regulator-like-2 exhibited anti-tumor effects and enhanced the sensitivity of colorectal cancer cells to oxaliplatin and 5-fluorouracil. OTT. 2019;12:8637\u201344.","journal-title":"OTT"},{"key":"8392_CR85","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner BC, Nardi V, Birsoy KK, Possemato R, Shen K, Sinha S, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014;4:554\u201363.","journal-title":"Cancer Discov"},{"key":"8392_CR86","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-018-0128-9","volume":"557","author":"J Chen","year":"2018","unstructured":"Chen J, Ou Y, Yang Y, Li W, Xu Y, Xie Y, et al. KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and ageing. Nature. 2018;557:585\u20139.","journal-title":"Nature"},{"key":"8392_CR87","doi-asserted-by":"publisher","first-page":"22746","DOI":"10.1073\/pnas.1914542116","volume":"116","author":"Y Pang","year":"2019","unstructured":"Pang Y, Xie F, Cao H, Wang C, Zhu M, Liu X, et al. Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2019;116:22746\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8392_CR88","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1053\/j.gastro.2022.11.014","volume":"164","author":"S Solanki","year":"2023","unstructured":"Solanki S, Sanchez K, Ponnusamy V, Kota V, Bell HN, Cho CS, et al. Dysregulated amino acid sensing drives colorectal cancer growth and metabolic reprogramming leading to chemoresistance. Gastroenterology. 2023;164:376\u2013.e13.","journal-title":"Gastroenterology"},{"key":"8392_CR89","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.12659\/MSM.909186","volume":"24","author":"S Liu","year":"2018","unstructured":"Liu S, Liu B. Overexpression of nitrogen permease regulator like-2 (NPRL2) enhances sensitivity to irinotecan (CPT-11) in colon cancer cells by activating the DNA damage checkpoint pathway. Med Sci Monit. 2018;24:1424\u201333.","journal-title":"Med Sci Monit"},{"key":"8392_CR90","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.98258.2","volume":"13","author":"IM Meraz","year":"2025","unstructured":"Meraz IM, Majidi M, Song R, Meng F, Gao L, Wang Q, et al. NPRL2 gene therapy induces effective antitumor immunity in KRAS\/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife. 2025;13.RP98258.","journal-title":"eLife"},{"key":"8392_CR91","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1158\/0008-5472.CAN-20-3232","volume":"81","author":"Y Cai","year":"2021","unstructured":"Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X, et al. Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3K\u03b1 inhibitors. Cancer Res. 2021;81:2470\u201380.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08392-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08392-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08392-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:02:13Z","timestamp":1769014933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08392-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8392"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08392-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}